Medical / Pharmaceuticals
Releases published in the last 30 days. 
Page 1 of 2
- Osteoboost Secures $8M to Expand Access to its FDA-Cleared Prescription Wearable for Bone Health
- 4/15/2026 12:00:00 PM
- Osteoboost Health, Inc., today announced it has closed an $8 million financing round to scale manufacturing, expand clinical research, and broaden the commercial reach of the company’s FDA-cleared medical device for low bone density.
- UK start-ups to power a new wave of quantum innovation
- 4/15/2026 11:02:24 AM
- The start-ups have joined the DeepTech Catalyst Quantum incubator programme (DTC Quantum), where they will use quantum technologies to develop and commercialise new products designed to deliver practical, real-world benefits.
- FDA Issues Draft Guidance on Genome Editing Safety Standards to Advance Gene Therapy Development
- 4/15/2026 10:11:56 AM
- The U.S. Food and Drug Administration issued a draft guidance for sponsors seeking approval of human gene therapy products involving genome editing technologies.
- AMA launches “Health vs. Hype” podcast series with iHeartMedia
- 4/15/2026 10:05:05 AM
- The American Medical Association (AMA), in collaboration with iHeartMedia’s Ruby studio, today announced the launch of its new podcast series, “Health vs.
- Osteoboost and Midi Health to Host Free Webinar on HRT and Bone Density for Women in Menopause
- 4/14/2026 12:03:23 PM
- Osteoboost Health, Inc. and Midi Health will co-host a free public webinar, HRT and the New Science of Strong Bones, on Thursday, April 16, 2026, at 2 p.m.
- Sanofi and Regeneron’s Dupixent approved in the EU as the first targeted medicine to treat young children with chronic spontaneous urticaria
- 4/13/2026 8:27:56 PM
- The European Commission has approved Dupixent (dupilumab) for the treatment of moderate-to-severe chronic spontaneous urticaria (CSU) in children aged two to 11 years with inadequate response to histamine-1 antihistamines (H1AH) and who are naïve to anti-immunoglobulin E (IgE) therapy for CSU.
- The Brain’s Emotional Hub Is Linked to Alcohol Use Differently in Young Men and Women
- 4/13/2026 12:39:16 PM
- New research shows that the threat-response in the brain’s amygdala (which processes emotions) is linked to different patterns of drinking by sex. In young males, heightened amygdala reactivity was linked to increased depressive symptoms, which in turn predicted heavier alcohol consumption.
- Ardian signs an agreement to acquire a stake in IVB Wellness Lab, a fast‑growing and innovative supplements brand in Spain
- 4/13/2026 4:24:41 AM
- IVB Wellness Lab (“IVB”), a leading Spanish company in the research, development and distribution of science‑backed dietary supplements, welcomes Ardian, a global private investment firm, as a minority shareholder.
- Food Literacy Program Helps Rural, Uninsured Patients With Diabetes Build Healthy Eating Skills
- 4/11/2026 8:58:11 AM
- A recent study in the Journal of Nutrition Education and Behavior (JNEB), published by Elsevier, examined the impact of a Food is Medicine (FIM) and food literacy education program on rural, uninsured adults with type 2 diabetes.
- First-ever WHO Forum unites 800+ Collaborating Centres for stronger scientific collaboration
- 4/10/2026 9:04:55 AM
- The World Health Organization (WHO) has convened the historic first Global Forum of Collaborating Centres—one of the world’s largest and most diverse public health networks—bringing together representatives from over 800 institutions designated as WHO Collaborating Centres (CCs) across more than 80 countries.
- A New Book Encourages Patients to Take Control of Their Healthcare
- 4/8/2026 2:54:37 PM
- For many people, healthcare has become increasingly complicated. Long wait times, rising costs, and confusing insurance requirements can leave patients feeling powerless at the very moment they need clarity the most.
- Johnson & Johnson Advances Pulsed Field Ablation Portfolio with the Launch of VARIPULSE Pro in Europe
- 4/8/2026 12:48:40 PM
- Johnson & Johnson announced the launch of VARIPULSE Pro in Europe following CE Mark approval, further advancing its pulsed field ablation (PFA) portfolio.
- Mila’s AI drives world’s largest study on psychedelics
- 4/8/2026 4:56:49 AM
- Psychedelics research is booming, with many research labs seeking cheaper, more effective alternative drug treatments to mental health conditions like depression and schizophrenia.
- From misdiagnosis to medical bias: Why women are living longer but not better
- 4/7/2026 4:16:16 PM
- Across the world, UN data shows, women are still less likely to be taken seriously, accurately diagnosed, or appropriately treated. From misdiagnosis to entrenched medical bias, gaps in healthcare systems continue to affect women’s health, safety and quality of life.
- AMA statement on Rx and Illicit Drug Summit
- 4/7/2026 2:15:04 PM
- Statement attributable to: Bobby Mukkamala, MD President, American Medical Association “As leaders from across medicine, pharmacy, and public health convene today at the Rx and Illicit Drug Summit, our message is clear: collaboration across care teams is essential to addressing the nation’s evolving substance use and overdose epidemic.
- Sanofi’s lunsekimig met primary and key secondary endpoints in phase 2 respiratory studies in asthma and CRSwNP
- 4/7/2026 11:17:25 AM
- • The AIRCULES phase 2b study achieved its primary and key secondary endpoints in moderate-to-severe asthma regardless of biomarker status • The DUET phase 2a study met its primary and key secondary endpoints in chronic rhinosinusitis with nasal polyps, reinforcing lunsekimig’s potential as a respiratory treatment • The exploratory VELVET phase 2b study did not meet …
- WHO calls for action: “Together for health. Stand with science.” to mark World Health Day
- 4/6/2026 12:26:46 PM
- The World Health Organization (WHO) today calls on people everywhere to renew their commitment to working together and supporting science as the twin engines driving better health, under the World Health Day 2026 theme: “Together for health.
- THMT Launches 2026 Premiere Issue
- 4/6/2026 8:30:00 AM
- The 2026 premiere issue of Telehealth and Medicine Today (THMT) is now live, marking a pivotal evolution in the journal’s leadership, editorial direction, and commitment to advancing virtual care.
- Urban health leaders renew commitment to accelerate life-saving action in cities
- 4/2/2026 12:53:10 PM
- As noncommunicable diseases and injuries continue to account for more than 80% of deaths worldwide, global urban health experts concluded the 2026 Partnership for Healthy Cities Summit in Rio de Janeiro this week with a renewed commitment to accelerate life-saving action in cities.
- Sanofi’s Rezurock approved in the EU to treat chronic graft-vs-host disease
- 4/1/2026 12:31:42 PM
- Sanofi’s Rezurock approved in the EU to treat chronic graft-vs-host disease • Rezurock is now approved in the EU for adults and children aged 12 years and older with chronic GVHD, providing a new medicine for patients with limited treatment options The European Commission has granted a conditional marketing authorisation for Rezurock (belumosudil) for the …